ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like 6 Biotechs Facing Key FDA Decisions in March February 26, 2017 U.S. House Passes Right-to-Try Legislation on Second Attempt March 21, 2018 Former Celator CPA Connived With Two Friends, Father on Insider-Trading Scheme August 31, 2017
